Nymox Pharmaceutical Corp., which sells tests for measuring tobacco product exposure, said Friday its third-quarter loss widened on higher costs and lower revenue.
The company reported a net loss of $1.76 million, or 5 cents per share, for the three months ended Sept, 30 compared with a loss of $1.36 million, or 4 cents per share, a year ago.
It said the larger loss was due to higher clinical trial expenditures compared to 2009.
Revenue fell to $26,896 from $71,904 a year ago. The decline reflected delays in production of inventory of NicAlert and TobacAlert tests for exposure to tobacco. The company said the problem has been corrected.
Shares of Nymox, which is based in St. Laurent, Quebec, rose 10 cents, or 2.5 percent, to $4.16 in afternoon trading. The stock has traded between $2.64 and $5.25 over the last 52 weeks.